Frontier Capital Management’s Cytokinetics CYTK Stock Holding History

Frontier Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,161	Closed	-$878K	–	261
2022 Q4	$878K	Sell	19,161 -140,053	-88%	-$6.03M	0.01%	256
2022 Q3	$7.71M	Buy	159,214 +102,355	+180%	+$4.93M	0.09%	215
2022 Q2	$2.23M	Sell	56,859 -352,691	-86%	-$14.2M	0.03%	266
2022 Q1	$15.1M	Sell	409,550 -251,265	-38%	-$8.93M	0.14%	185
2021 Q4	$30.1M	Sell	660,815 -94,623	-13%	-$3.65M	0.24%	138
2021 Q3	$27M	Buy	+755,438	New	+$22.2M	0.21%	148

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Frontier Capital Management's CYTK Position: Q1 2023 in Review

Frontier Capital Management sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 19,161 shares — an estimated $878K sold.

Frontier Capital Management first reported a position in CYTK in Q3 2021 and held it in 6 quarters. The position peaked at $30.1M in Q4 2021. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

Frontier Capital Management reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
Frontier Capital Management sold 19,161 Cytokinetics shares in Q1 2023, an estimated $878K.
Frontier Capital Management first reported a position in Cytokinetics in Q3 2021 and held it in 6 quarters.
Frontier Capital Management's Cytokinetics position peaked at $30.1M in Q4 2021.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Frontier Capital Management's 13F filing for Q1 2023, filed 15 May 2023.